Pazopanib: therapeutic developments

Expert Opin Pharmacother. 2009 Dec;10(18):3091-102. doi: 10.1517/14656560903436493.

Abstract

Pazopanib (Votrient, GW786034) is a potent pan-VEGF inhibitor in advanced clinical development. Like other orally available VEGFR inhibitors, pazopanib is clinically efficacious and well tolerated. The recently reported Phase III clinical trial in metastatic renal cell carcinoma showed activity similar to approved agents with variations in toxicity which has led to its recent FDA approval. Given the growing number of agents in this category, differences not only in single-agent activity but also toxicity and combinatorial potency will probably distinguish pazopanib from other similar agents.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy
  • Clinical Trials as Topic
  • Drug Screening Assays, Antitumor
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Kidney Neoplasms / drug therapy
  • Neoplasms / drug therapy*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use*
  • Vascular Endothelial Growth Factors / antagonists & inhibitors

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Vascular Endothelial Growth Factors
  • pazopanib
  • Protein-Tyrosine Kinases
  • Receptors, Vascular Endothelial Growth Factor